Integrating clinical decision support systems for pharmacogenomic testing into clinical routine - a scoping review of designs of user-system interactions in recent system development

BackgroundPharmacogenomic clinical decision support systems (CDSS) have the potential to help overcome some of the barriers for translating pharmacogenomic knowledge into clinical routine. Before developing a prototype it is crucial for developers to know which pharmacogenomic CDSS features and user-system interactions have yet been developed, implemented and tested in previous pharmacogenomic CDSS efforts and if they have been successfully applied. We address this issue by providing an overview of the designs of user-system interactions of recently developed pharmacogenomic CDSS.MethodsWe searched PubMed for pharmacogenomic CDSS published between January 1, 2012 and November 15, 2016. Thirty-two out of 118 identified articles were summarized and included in the final analysis. We then compared the designs of user-system interactions of the 20 pharmacogenomic CDSS we had identified.ResultsAlerts are the most widespread tools for physician-system interactions, but need to be implemented carefully to prevent alert fatigue and avoid liabilities. Pharmacogenomic test results and override reasons stored in the local EHR might help communicate pharmacogenomic information to other internal care providers. Integrating patients into user-system interactions through patient letters and online portals might be crucial for transferring pharmacogenomic data to external health care providers. Inbox messages inform physicians about new pharmacogenomic test results and enable them to request pharmacogenomic consultations. Search engines enable physicians to compare medical treatment options based on a patient’s genotype.ConclusionsWithin the last 5 years, several pharmacogenomic CDSS have been developed. However, most of the included articles are solely describing prototypes of pharmacogenomic CDSS rather than evaluating them. To support the development of prototypes further evaluation efforts will be necessary. In the future, pharmacogenomic CDSS will likely include prediction models to identify patients who are suitable for preemptive genotyping.

[1]  D. Moher,et al.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. , 2010, International journal of surgery.

[2]  Teri E. Klein,et al.  Incorporation of Pharmacogenomics into Routine Clinical Practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline Development Process , 2014, Current drug metabolism.

[3]  Mike Conway,et al.  Extracting a stroke phenotype risk factor from Veteran Health Administration clinical reports: an information content analysis , 2016, Journal of Biomedical Semantics.

[4]  R. Weinshilboum.  Inheritance and drug response. , 2003, The New England journal of medicine.

[5]  Casey Lynnette Overby,et al.  Making pharmacogenomic-based prescribing alerts more effective: A scenario-based pilot study with physicians , 2015, J. Biomed. Informatics.

[6]  Peter Tarczy-Hornoch,et al.  Physician perspectives of CYP2C19 and clopidogrel drug-gene interaction active clinical decision support alerts , 2016, Int. J. Medical Informatics.

[7]  D. Moher,et al.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement , 2009, BMJ.

[8]  Peter Tarczy-Hornoch,et al.  Development of clinical decision support alerts for pharmacogenomic incidental findings from exome sequencing , 2015, Genetics in Medicine.

[9]  E. Clayton,et al.  Operational Implementation of Prospective Genotyping for Personalized Medicine: The Design of the Vanderbilt PREDICT Project , 2012, Clinical pharmacology and therapeutics.

[10]  Hallvard Lærum,et al.  A taste of individualized medicine: physicians' reactions to automated genetic interpretations. , 2014, Journal of the American Medical Informatics Association : JAMIA.

[11]  Yee Ming Lee,et al.  Disease–drug database for pharmacogenomic‐based prescribing , 2016, Clinical pharmacology and therapeutics.

[12]  M. Relling,et al.  Development and use of active clinical decision support for preemptive pharmacogenomics , 2013, Journal of the American Medical Informatics Association : JAMIA.

[13]  Peter Tarczy-Hornoch,et al.  Usability evaluation of pharmacogenomics clinical decision support aids and clinical knowledge resources in a computerized provider order entry system: A mixed methods approach , 2014, Int. J. Medical Informatics.

[14]  C. Altar,et al.  Clinical validity: Combinatorial pharmacogenomics predicts antidepressant responses and healthcare utilizations better than single gene phenotypes , 2015, The Pharmacogenomics Journal.

[15]  D. Brixner,et al.  The effect of pharmacogenetic profiling with a clinical decision support tool on healthcare resource utilization and estimated costs in the elderly exposed to polypharmacy , 2016, Journal of medical economics.

[16]  Kenneth D Mandl,et al.  Development of a scalable pharmacogenomic clinical decision support service. , 2013, AMIA Joint Summits on Translational Science proceedings. AMIA Joint Summits on Translational Science.

[17]  K. J. Johansen Taber,et al.  Pharmacogenomic knowledge gaps and educational resource needs among physicians in selected specialties , 2014, Pharmacogenomics and personalized medicine.

[18]  H. Guchelaar,et al.  Pharmacogenetics: From Bench to Byte— An Update of Guidelines , 2011, Clinical pharmacology and therapeutics.

[19]  Frank Puppe,et al.  A Diagnostic Expert System for Structured Reports, Quality Assessment, and Training of Residents in Sonography , 2004, Medizinische Klinik.

[20]  M. Relling,et al.  Preemptive Clinical Pharmacogenetics Implementation: Current programs in five United States medical centers , 2015 .

[21]  Joshua C Denny,et al.  A prognostic model based on readily available clinical data enriched a pre-emptive pharmacogenetic testing program. , 2016, Journal of clinical epidemiology.

[22]  Yuan Ji,et al.  Preemptive Pharmacogenomic Testing for Precision Medicine: A Comprehensive Analysis of Five Actionable Pharmacogenomic Genes Using Next-Generation DNA Sequencing and a Customized CYP2D6 Genotyping Cascade. , 2016, The Journal of molecular diagnostics : JMD.

[23]  Soma Das,et al.  Adoption of a clinical pharmacogenomics implementation program during outpatient care–initial results of the University of Chicago “1,200 Patients Project” , 2014, American journal of medical genetics. Part C, Seminars in medical genetics.

[24]  Hans-Ulrich Kauczor,et al.  Development, Implementation, and Evaluation of a Structured Reporting Web Tool for Abdominal Aortic Aneurysms , 2013, JMIR research protocols.

[25]  M. Relling,et al.  Pharmacogenetics for Safe Codeine Use in Sickle Cell Disease , 2016, Pediatrics.

[26]  J. Hoffman,et al.  Integrating pharmacogenomics into electronic health records with clinical decision support. , 2016, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[27]  Charis Eng,et al.  Implementation of Clinical Pharmacogenomics within a Large Health System: From Electronic Health Record Decision Support to Consultation Services , 2016, Pharmacotherapy.

[28]  T Treasure,et al.  Clinical reports of pulmonary metastasectomy for colorectal cancer: a citation network analysis , 2011, British Journal of Cancer.

[29]  Martin Dawes,et al.  Introducing pharmacogenetic testing with clinical decision support into primary care: a feasibility study. , 2016, CMAJ open.

[30]  M. Simoons,et al.  Individualized Angiotensin‐Converting Enzyme (ACE)‐Inhibitor Therapy in Stable Coronary Artery Disease Based on Clinical and Pharmacogenetic Determinants: The PERindopril GENEtic (PERGENE) Risk Model , 2016, Journal of the American Heart Association.

[31]  J. Finkelstein,et al.  A Use Case to Support Precision Medicine for Frequently Hospitalized Older Adults with Polypharmacy , 2016, AMIA Joint Summits on Translational Science proceedings. AMIA Joint Summits on Translational Science.

[32]  P. Binkley,et al.  Design and Implementation of a Randomized Controlled Trial of Genomic Counseling for Patients with Chronic Disease , 2014, Journal of personalized medicine.

[33]  Ching-Hon Pui,et al.  PG4KDS: A model for the clinical implementation of pre‐emptive pharmacogenetics , 2014, American journal of medical genetics. Part C, Seminars in medical genetics.

[34]  Jeffrey C. Hall,et al.  The CLIPMERGE PGx Program: Clinical Implementation of Personalized Medicine Through Electronic Health Records and Genomics–Pharmacogenomics , 2013, Clinical pharmacology and therapeutics.

[35]  Alissa L. Russ,et al.  Iterative Development and Evaluation of a Pharmacogenomic-Guided Clinical Decision Support System for Warfarin Dosing , 2016, Applied Clinical Informatics.

[36]  J. Ioannidis,et al.  The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration , 2009, Annals of Internal Medicine [serial online].

[37]  Cloann Schultz,et al.  Evaluation of the use of clinical decision support and online resources for pharmacogenomics education. , 2015, Pharmacogenomics.

[38]  P. Le Beux,et al.  Combining voice recognition and automatic indexing of medical reports. , 2002, Studies in health technology and informatics.

[39]  Kevin B. Johnson,et al.  Electronic health record design and implementation for pharmacogenomics: a local perspective , 2013, Genetics in Medicine.

[40]  Kenneth D. Mandl,et al.  Creating a scalable clinical pharmacogenomics service with automated interpretation and medical record result integration – experience from a pediatric tertiary care facility , 2017, J. Am. Medical Informatics Assoc..

[41]  Teri E Klein,et al.  Preemptive clinical pharmacogenetics implementation: current programs in five US medical centers. , 2015, Annual review of pharmacology and toxicology.

[42]  Kristin A. Maloney,et al.  The Pharmacogenomics Research Network Translational Pharmacogenetics Program: Overcoming Challenges of Real‐World Implementation , 2013, Clinical pharmacology and therapeutics.

[43]  Julie A. Johnson,et al.  Emerging Roles for Pharmacists in Clinical Implementation of Pharmacogenomics , 2014, Pharmacotherapy.

[44]  José Antonio Miñarro-Giménez,et al.  An Ontology-Based, Mobile-Optimized System for Pharmacogenomic Decision Support at the Point-of-Care , 2014, PloS one.

[45]  Guilherme Del Fiol,et al.  Developing a Prototype System for Integrating Pharmacogenomics Findings into Clinical Practice , 2012, Journal of personalized medicine.

[46]  R. Verbrugge,et al.  Adoption of Pharmacogenomic Testing by US Physicians: Results of a Nationwide Survey , 2012, Clinical pharmacology and therapeutics.

[47]  Gianrico Farrugia,et al.  Multidisciplinary Model to Implement Pharmacogenomics at the Point of Care , 2016, Genetics in Medicine.

[48]  Joseph Finkelstein,et al.  Potential utility of precision medicine for older adults with polypharmacy: a case series study , 2016, Pharmacogenomics and personalized medicine.

[49]  Jon W. McKeeby,et al.  Integrating pharmacogenetic information and clinical decision support into the electronic health record , 2014, J. Am. Medical Informatics Assoc..

[50]  Matthias Samwald,et al.  Examining perceptions of the usefulness and usability of a mobile-based system for pharmacogenomics clinical decision support: a mixed methods study , 2016, PeerJ.

[51]  Kensaku Kawamoto,et al.  Clinical decision support for genetically guided personalized medicine: a systematic review , 2013, J. Am. Medical Informatics Assoc..